Yellow fever vaccination: Is one dose always enough?

Travel Medicine and Infectious Disease

Volumn 11, Issue 5, 2013, Pages 266-273

  Patel, Dipti ^a,c,d   Simons, Hilary ^a,b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^c FOREIGN AND COMMONWEALTH OFFICE   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Booster; Health; Immunity; International; Regulations; Vaccine efficacy

Indexed keywords

NEUTRALIZING ANTIBODY; YELLOW FEVER VACCINE;

DRUG EFFICACY; DRUG SAFETY; EMPORIATRICS; HEALTH PRACTITIONER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; INFECTION PREVENTION; INFECTION RISK; MALNUTRITION; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; SINGLE DRUG DOSE; TRAVEL; VACCINATION; VACCINATION REACTION; WORLD HEALTH ORGANIZATION; YELLOW FEVER;

BOOSTER; IMMUNITY; INTERNATIONAL HEALTH REGULATIONS; VACCINE EFFICACY;

AFRICA; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; SOUTH AMERICA; TRAVEL MEDICINE; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 84885617535     PISSN: 14778939     EISSN: 18730442     Source Type: Journal    
DOI: 10.1016/j.tmaid.2013.08.007     Document Type: Review

References (36)

1. E.S. Jentes, G. Poumerol, M.D. Gershman, D.R. Hill, J. Lemarchand, and R.F. Lewis The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the informal WHO working group on geographic risk for yellow fever Lancet Infect Dis 11 8 2011 Aug 622 632 10.1016/S1473-3099(11)70147-5
2. World Health Organization International Health Regulations 2005 Available at: http://www.who.int/ihr/9789241596664/en/index.html
3. World Health Organization. Yellow fever vaccination requirements and recommendations. International Travel and Health. Available at: http://www.who.int/ith/chapters/en/index.html.
4. Background for the Consultation on Yellow Fever and International Travel Informal working group on geographic risk of yellow fever (update February 2011) 2010 World Health Organization Available at: http://www.who.int/ith/YFrisk.pdf
5. B.A. Lown, L.H. Chen, M.E. Wilson, E. Sisson, M. Gershman, and E. Yanni Vaccine administration decision making: the case of yellow fever vaccine Clin Infect Dis 55 6 2012 Sept 837 843
6. E.S. Jentes, P. Han, M.D. Gershman, S.R. Rao, R.C. LaRocque, and J.E. Staples Travel characteristics and yellow fever vaccine usage among US Global TravEpiNet travelers visiting countries with risk of yellow fever virus transmission, 2009-2011 Am J Trop Med Hyg 88 5 2013 May 954 961
7. R.E. Thomas, D.L. Lorenzetti, W. Spragins, D. Jackson, and T. Williamson Reporting rates of yellow fever 17D or 17DD - associated serious adverse events in pharmacovigilance databases: systematic review Curr Drug Saf 6 3 2011 Jul 145 154
8. T.P. Monath, M. Gershman, J.E. Staples, and A.D.T. Barrett Yellow fever vaccine S.A. Plotkin, W. Orenstein, P.A. Offit, Vaccines 6th ed. 2013 Saunders Elsevier
9. M. Martin, T.F. Tsai, B. Cropp, G.J. Chang, D.A. Holmes, and J. Tseng Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases Lancet 358 9276 2001 98 104
10. R.W. Douce, D. Freire, B. Tello, and G.A. Vásques Case report: a case of yellow fever vaccine-associated viscerotropic disease in Ecuador Am J Trop Med Hyg 84 4 2010 741 742
11. A. Whittembury, G. Ramirez, H. Hernández, A.M. Ropero, S. Waterman, and M. Ticona Viscerotropic disease following yellow fever vaccination in Peru Vaccine 27 43 2009 Oct 9 5974 5981 10.1016/j.vaccine.2009.07.082 Epub 2009 Aug 11
12. World Health Organization. Background paper on yellow fever vaccine. SAGE Working Group. Available at: http://www.who.int/immunization/sage/meetings/ 2013/april/1-Background-Paper-Yellow-Fever-Vaccines.pdf.
13. G. Courtois Time of appearance and duration of immunity conferred by 17D vaccine Yellow fever vaccine 1956 WHO Series Geneva, Switzerland
14. T.P. Monath Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans Am J Epidemiol 93 1971 122 129
15. T.P. Monath, K. McCarthy, P. Bedford, C.T. Johnson, R. Nichols, and S. Yoksan Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections Vaccine 20 2002 1004 1018
16. T.P. Monath, R. Nichols, W.T. Archambault, L. Moore, R. Marchesani, and J. Tian Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III, multicentre, double blind clinical trial Am J Trop Med Hyg 66 5 2002 533 541
17. E.C. Rosenzweig, R.W. Babione, and C.L. Wisseman Jr. Immunological studies with group B arthropod-borne viruses. IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine Am J Trop Med Hyg 12 1963 230 235
18. J.D. Poland, C.H. Calisher, T.P. Monath, W.G. Downs, and K. Murphy Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine Bull World Health Organ 59 1981 895 900
19. Gotuzzo E, Córdova GR. Efficacy and duration of immunity following yellow fever vaccine: a systematic review on the need of yellow fever booster every 10 years. Available at: http://www.who.int/immunization/sage/meetings/ 2013/april/3-YF-BOOSTER-FINAL-DRAFT2.pdf.
20. World Health Organization Yellow fever vaccine. WHO position paper Wkly Epidemiol Rec 78 40 2003 Oct 3 349 359
21. World Health Organization Vaccines and vaccination against yellow fever. WHO position paper June 2013 Wkly Epidemiol Rec 27 88 2013 269 284
22. M.P. Grobulsh, A. Goorhuis, R.W. Wieten, JD. Verberk, E.F. Jonker, and P.J. van Genderen Yellow fever re-vaccination guidelines change - a decision too feverish? Clin Microbiol Infect 2013 Jul 13 10.1111/1469-0691.12332
23. N.L. Boddington, H. Simons, N. Launders, and D.R. Hill Quality improvement in travel medicine: a programme for yellow fever vaccination centres in England, Wales and Northern Ireland Qual Prim Care 19 6 2011 391 398
24. G.W.A. Dick, and F.L. Gee Immunity to yellow fever nine years after vaccination Trans R Soc Trop Med Hyg 46 4 1952 449 458
25. H. Groot, and R.B. Riberiro Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine Bull World Health Organ 27 1962 699 707
26. B. Reinhardt, R. Jaspert, M. Niedrig, C. Kostner, and J. L'age-Stehr Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection J Med Virol 56 1998 159 167
27. M. Niedrig, M. Lademann, P. Emmerich, and M. Lafrenz Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA Trop Med Int Health 4 1999 867 871
28. S.Y. Gomez, and R.E. Ocazionez Yellow fever virus 17D neutralizing antibodies in vaccinated Colombian people and unvaccinated ones having immunity against dengue Rev Salud Publica 10 2008 796 807
29. A.B. de Melo, P. da Silva Mda, M.C. Magalhaes, L.H. Gonzales Gil, EM. Carvalho, and U.M. Braga-Neto Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil Am J Trop Med Hyg 85 2011 739 747
30. H.C. Bodilis, G. Benabdelmoumen, A. Gergely, C. Goujon, M. Pelicot, and P. Poujol Persistance à long terme des anticorps neutralisants de la fièvre jaune chez les personnes âgées de 60 ans et plus: long term persistance of yellow fever neutralising antibodies in elderly persons Long-term persistence of yellow fever neutralizing antibodies in persons aged 60 years and older Bull Soc Pathol Exot 104 2011 260 265
31. K.J. Rothman Epidemiology - an introduction 2012 Oxford University Press New York
32. J.R. Nascimento Silva, L.A. Camacho, M.M. Siqueira, S. Freire Mde, Y.P. Castro, and L. Maia Mde Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles mumps and rubella Vaccine 29 3 2011 6327 6334
33. T. Monath Review of the risks and benefits of yellow fever vaccination including some new analyses Expert Rev Vaccines 4 2012 427 448
34. Centers for Disease Control and Prevention Yellow fever vaccine. Recommendations of the Advisory Committee on Immunisation Practices (ACIP) Morbidity Mortality Weekly Rep 59 RR-7 July 30 2010
35. M.J. Hepburn, M.G. Kortepeter, P.R. Pittman, E.F. Boudreau, J.A. Mangiafico, and P.A. Buck Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine Vaccine 24 15 2006 Apr 5 2843 2849 Epub 2006 Jan 18
36. A.M. Geretti, BHIVA Immunization Writing Committee, G. Brook, C. Cameron, D. Chadwick, and R.S. Heyderman British HIV association guidelines for immunization of HIV-infected adults 2008 HIV Med 9 10 2008 Nov 795 848 10.1111/j.1468-1293.2008.00637.x